Affiliation:
1. Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital, Sichuan University Chengdu Sichuan China
Abstract
AbstractAs the fifth variant of concern of the SARS‐CoV‐2 virus, the Omicron variant (B.1.1.529) has quickly become the dominant type among the previous circulating variants worldwide. During the Omicron wave, several subvariants have emerged, with some exhibiting greater infectivity and immune evasion, accounting for their fast spread across many countries. Recently, two Omicron subvariants, BQ.1 and XBB lineages, including BQ.1.1, XBB.1, and XBB.1.5, have become a global public health issue given their ability to escape from therapeutic monoclonal antibodies and herd immunity induced by prior coronavirus disease 2019 (COVID‐19) vaccines, boosters, and infection. In this respect, XBB.1.5, which has been established to harbor a rare mutation F486P, demonstrates superior transmissibility and immune escape ability compared to other subvariants and has emerged as the dominant strain in several countries. This review provides a comprehensive overview of the epidemiological features, spike mutations, and immune evasion of BQ.1 and XBB lineages. We expounded on the mechanisms underlying mutations and immune escape from neutralizing antibodies from vaccinated or convalescent COVID‐19 individuals and therapeutic monoclonal antibodies (mAbs) and proposed strategies for prevention against BQ.1 and XBB sublineages.
Subject
Cell Biology,Biochemistry (medical),Genetics (clinical),Computer Science Applications,Drug Discovery,Genetics,Oncology,Immunology and Allergy
Reference59 articles.
1. WHO.WHO Coronavirus (COVID‐19) Dashboard.2023. Accessed January 16 2023.https://covid19.who.int/
2. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
3. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
4. WHO.Tracking SARS‐CoV‐2 variants.2023. Accessed January 16 2023.https://www.who.int/activities/tracking‐SARS‐CoV‐2‐variants/tracking‐SARS‐CoV‐2‐variants
5. WHO.Statement on Omicron sublineages BQ.1 and XBB.2023. Accessed January 16 2023.https://www.who.int/news/item/27‐10‐2022‐tag‐ve‐statement‐on‐omicron‐sublineages‐bq.1‐and‐xbb
Cited by
64 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献